Loading…
Edgewise Therapeutics, Inc. is projected to rise to $50.25 by 2027, a +22% move from its current price of $41.12. EWTX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $39.75 | $41.13 | $42.56 | +0.02% |
| Aug 2 | $39.20 | $41.14 | $43.17 | +0.05% |
| Aug 3 | $38.79 | $41.15 | $43.65 | +0.07% |
| Aug 4 | $38.45 | $41.16 | $44.06 | +0.10% |
| Aug 5 | $38.15 | $41.17 | $44.43 | +0.12% |
| Aug 6 | $37.88 | $41.18 | $44.77 | +0.14% |
| Aug 7 | $37.64 | $41.19 | $45.08 | +0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $37.64 | $41.19 | $45.08 | +0.17% |
| Week 2 | $36.32 | $41.26 | $46.87 | +0.34% |
| Week 3 | $35.35 | $41.33 | $48.32 | +0.50% |
| Week 4 | $34.56 | $41.40 | $49.58 | +0.67% |
| Week 5 | $33.89 | $41.47 | $50.73 | +0.84% |
| Week 6 | $33.30 | $41.54 | $51.81 | +1.01% |
| Week 7 | $32.77 | $41.60 | $52.82 | +1.18% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Edgewise Therapeutics, Inc. is a biopharmaceutical company that discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, is an orally administered small molecule that is in Phase II clinical trials designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
The company also develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials, and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction, along with a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Edgewise Therapeutics, Inc. (EWTX) is currently priced at $40.83, with a market capitalization of $4.39B. It ranks 1,479 in market cap terms. The forecast shows a price path with an average around $40.83 in 2026, rising through subsequent years to higher levels, including an average of $90.57 by 2030 and $602.45 by 2050.
The forecast also points to a 2050 max of $1,303.49, underscoring a long-run upside potential. The 30-day technical picture features a 30-day range from $31.40 to $53.08, with a volatility profile and a bullish overall stance implied by the numbers. The current market conditions include a 30-day volatility figure of 80% and supportive levels near $32.92 with resistance near $48.35, reflecting a structured range around the current price.
A major floor 32.1% below — a decisive break under it would weaken the trend.
The nearest floor, 15.3% below — buyers have tended to step in here.
The nearest ceiling, 17.6% above — a clean break opens room to run.
A major ceiling 33.7% above — clearing it would confirm fresh momentum.
Key EWTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EWTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $40.73 | Buy | $40.49 | Buy |
| MA 10 | $39.94 | Buy | $40.40 | Buy |
| MA 20 | $41.11 | Buy | $40.24 | Buy |
| MA 50 | $38.12 | Buy | $38.45 | Buy |
| MA 100 | $35.13 | Buy | $35.49 | Buy |
| MA 200 | $29.60 | Buy | $31.08 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.40 | Neutral |
| Stoch RSI (14) | 82.65 | Sell |
| CCI (20) | 0.17 | Neutral |
| Williams %R (14) | -14.08 | Info |
| MACD (12,26,9) | -0.22 | Sell |
| ROC (12) | 3.50 | Buy |
| Bollinger %B (20,2) | 0.50 | Neutral |
| Stochastic %K (14) | 85.92 | Sell |
| TRIX (15) | 0.26 | Buy |
| Awesome (5,34) | 0.93 | Buy |
| Ultimate (7,14,28) | 53.42 | Neutral |
| Momentum (10) | 2.93 | Buy |
| Aroon Osc (25) | -20.00 | Sell |
| Hull MA (9) | 40.93 | Buy |
| ADX (14) | 10.79 | Neutral |
| ATR (14) | 1.38 | Info |
The near-term technical picture leans bullish, with RSI(14) at 50 and moving averages guiding near-term momentum. The 50-day simple moving average sits at $36.94, while the 200-day simple moving average sits at $28.27, offering a constructive baseline for price action. The stock has a defined 30-day range of $31.40 to $53.08, suggesting considerable exploration of upside and downside within a single month.
Support is identified at $32.92 and resistance at $48.35, indicating a well-defined trading corridor.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $22.94 | $41.12 | $54.81 | 0% | Neutral | |
| $39.16 | $50.25 | $68.69 | +22% | Bullish | |
| $39.49 | $52.53 | $75.15 | +28% | Bullish | |
| $49.92 | $68.45 | $101.40 | +66% | Bullish | |
| $65.84 | $92.71 | $141.42 | +125% | Bullish | |
| $73.44 | $105.98 | $165.82 | +158% | Bullish | |
| $79.32 | $117.10 | $187.41 | +185% | Bullish | |
| $83.38 | $125.78 | $205.45 | +206% | Bullish | |
| $89.50 | $137.82 | $229.37 | +235% | Bullish | |
| $93.88 | $147.46 | $249.70 | +259% | Bullish | |
| $150.01 | $258.08 | $469.69 | +528% | Bullish | |
| $320.85 | $649.13 | $1,310.45 | +14.8x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $22.94 | $41.12 | $48.00 | +0.00% |
| August 2026 | $34.38 | $40.57 | $49.13 | -1.35% |
| September 2026 | $35.25 | $42.03 | $51.75 | +3.60% |
| October 2026 | $36.51 | $43.90 | $54.76 | +4.45% |
| November 2026 | $35.91 | $43.48 | $54.81 | -0.96% |
| December 2026 | $35.34 | $43.07 | $54.81 | -0.94% |
Click any year to see its month-by-month EWTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect EWTX to range from $22.94 to $54.81 through 2026. The $41.12 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The EWTX price prediction for 2027 points to an average of $50.25 (low $39.16, high $68.69) — a potential gain of +22% on today's $41.12. Momentum favours further upside here.
In 2028, EWTX is projected to trade between $39.49 and $75.15, averaging $52.53 — a potential gain of +28% from today's $41.12. That is up +5% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Edgewise Therapeutics, Inc.'s 2029 outlook centres on $68.45, within a $49.92 to $101.40 range. That is up +30% on the projected 2028 average. That marks a +66% change versus current levels. Momentum favours further upside here.
By 2030, EWTX could reach as high as $141.42, with a base case around $92.71 and support toward $65.84 — roughly +125% from $41.12. Buyers look set to stay in control over this stretch.
Expect EWTX to range from $73.44 to $165.82 through 2031. The $105.98 average target implies a +158% move from current prices. That is up +14% on the projected 2030 average. Momentum favours further upside here.
The EWTX price prediction for 2032 points to an average of $117.10 (low $79.32, high $187.41) — a potential gain of +185% on today's $41.12. Buyers look set to stay in control over this stretch.
In 2033, EWTX is projected to trade between $83.38 and $205.45, averaging $125.78 — a potential gain of +206% from today's $41.12. That is up +7% on the projected 2032 average. Momentum favours further upside here.
Edgewise Therapeutics, Inc.'s 2034 outlook centres on $137.82, within a $89.50 to $229.37 range. That is up +10% on the projected 2033 average. That marks a +235% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, EWTX could reach as high as $249.70, with a base case around $147.46 and support toward $93.88 — roughly +259% from $41.12. Momentum favours further upside here.
Expect EWTX to range from $150.01 to $469.69 through 2040. The $258.08 average target implies a +528% move from current prices. That is up +75% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The EWTX price prediction for 2050 points to an average of $649.13 (low $320.85, high $1,310.45) — a potential gain of +14.8x on today's $41.12. Momentum favours further upside here.
Investing $1,000 in EWTX today (≈ 24.319066 EWTX) could be worth
$15,786.17
+$14,786.17 (+1479%) by 2050 · US Dollar
Based on the average projected EWTX price of $649.13 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EWTXwould be worth at today's price.
$1,000 invested in EWTX on Jul 30, 2025 (≈ 70.274071 EWTX) would be worth
$2,889.67
+$1,889.67 (+189.0%) today · 2.89× · US Dollar
Based on a EWTX entry price of $14.23 vs. today's $41.12.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $39.29 | $1,046.58 | +4.7% |
| 1 month ago | $40.63 | $1,012.06 | +1.2% |
| 3 months ago | $30.61 | $1,343.35 | +34.3% |
| 6 months ago | $28.15 | $1,460.75 | +46.1% |
| 1 year ago | $14.23 | $2,889.67 | +189.0% |
| All time (5.0y) ago | $17.44 | $2,357.8 | +135.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EWTX forecast.
Our base-case forecast reaches $82.00 around 2030.
Implied market cap at $82.00: $8.82B
The multi-year forecast outlines a pronounced upside trajectory, with 2030 averaging $90.57 and 2040 averaging $230.58, and 2050 averaging $602.45. The forecast shows a strong long-run upside, with 2030 ROI of 121.8 and 2040 ROI of 464.7, culminating in 2050 ROI of 1375.5. Sentiment shifts to bullish from 2029 onward, signaling durable optimism about long-run performance, though the earliest years show neutral sentiment (2026–2028).
The 2050 horizon includes a max of $1,303.49, illustrating the potential scale of gains under the modeled path. These are estimates, not guarantees, and actual results may differ due to market dynamics and clinical/operational developments.
Tap a question to reveal the answer.
Avg price by 2030 is $90.57; min $61.81; max $143.88; ROI 121.8; sentiment BULLISH.
The forecast shows a long-run upside with 2050 avg $602.45 and 2050 max $1,303.49; ROI 1375.5; however, 2026–2028 show neutral sentiment with near-term values around $40.83, and these are estimates, not guarantees.
Yes, the 2050 max is $1,303.49, which exceeds $1,000.
The 30-day range is $31.40 to $53.08; RSI(14) is 50; SMA(50) is $36.94; SMA(200) is $28.27; support is $32.92; resistance is $48.35.
Current price is $40.83 and market cap is $4.39B.
Edgewise Therapeutics, Inc. Community Discussion
0Share your Edgewise Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.